Colorectal Cancer Screening Market Size, Share & Industry Analysis, By Type (Stool-based (Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), and Stool-DNA Test), Colonoscopy, and Others), By End-user (Hospitals & Clinics, Clinical Laboratories, Diagnostics Imaging Centers, and Others), and Regional Forecast, 2024-2032

The global colorectal cancer screening market size was valued at USD 17.05 billion in 2023, and  is projected to grow from USD 17.83 billion in 2024 to USD 24.65 billion by 2032, exhibiting a CAGR of 4.1% during the forecast period. North America dominated the global market with a share of 64.81% in 2023. Moreover, the U.S. colorectal cancer screening market size is projected to grow significantly, reaching an estimated value of USD 17.53 billion by 2032, driven by growing incidence of colorectal cancer.

Colorectal Cancer (CRC) occurs when the cancerous cells begin to grow and spread in the colon or rectum part of the digestive tract, and adults aged 45 and above are more prone to it. If these cancers are detected at early stages, effective treatments can be provided. Colorectal cancer screening helps in detecting the cancer in asymptomatic and high-risk patients who are aged 45 and above. Therefore, the increasing prevalence of colorectal cancer and rising government initiatives to create awareness have been fueling the demand for these screening tests.

• For instance, as per data published by the World Health Organization (WHO) in 2023, around 1.9 million new colorectal cancer cases occurred globally in 2020. Moreover, in the same year, around 930,000 deaths occurred due to colorectal cancer.

Furthermore, due to the sudden outbreak of COVID-19 in 2020, the market experienced a decline in its revenue due to the limited number of screening procedures being conducted in that year. However, in 2021 and 2022, the market experienced significant growth due to the increasing burden of the disease globally and a rise in the number of CRC screening.

Colorectal Cancer Screening Market Trends

Emergence of New Technologies to Boost the Market Growth

The market players have increased their focus on the development and commercialization of technologically advanced products for efficient screening due to the increasing incidence of colorectal cancer globally and increasing awareness regarding the early testing and treatment of the disease.

Moreover, the adoption of new advanced technologies to enhance the efficiency of screening procedures has also been rising significantly.

• For instance, in August 2023, United Digestive, a GI management company, announced the launch of their colonoscopy offering through the GI Genius endoscopy module, a product by Medtronic plc. The GI Genius module uses artificial intelligence to detect colorectal polyps, providing physicians with a powerful new solution to help patients fight against CRC.

The approval and commercialization of these screening tests are expected to encourage other market players to launch more tests to increase the volume of tests for colorectal cancer during the forecast period.

Such new technologies for the detection of CRC are increasing the adoption of tests, thereby fueling the overall market growth.

Colorectal Cancer Screening Market Growth Factors

Government Initiatives and Policies Associated with Cancer Screening Tests to Drive the Market

Governments across various countries have increased the policies for colorectal cancer screening to reduce the disease globally. To control the increasing burden of CRC, governments across many countries have taken certain initiatives such as regular screening programs for individuals who are at risk of getting affected by the disease. Many countries have increased their emphasis on the development of policies to increase the screening rates for colorectal cancer.

These programs help detect CRC at minimal cost. They are one of the prominent factors increasing the number of screening procedures being conducted globally, especially in developed countries such as the U.S., South Korea, and the U.K.

• For instance, as per data published by BioMed Central Ltd, in 2021, the National Cancer Screening Program (NCSP) offers CRC screening at no cost in the Republic of Korea.

The increasing aging population, coupled with government initiatives, are expected to propel the adoption of various tests, thereby fueling the overall market growth.

Increasing Incidence of Colorectal Cancer to Boost the Market Growth

One of the major drivers that is positively impacting the growth of the market is the significant increase in the incidence of colorectal cancer globally. The incidence is higher in developed countries, and it is increasing in middle- and low-income countries due to unhealthy lifestyle choices and a surge in the aging population in these countries. 

• For instance, in 2020, the American Cancer Society, Inc. estimated that rectal cancer and colon cancer cases diagnosed in the U.S. were 43,340 and 104,610, respectively.


• Similarly, as per an article published by ScienceDirect in 2021, an estimated 1.93 million new CRC cases were diagnosed in 2020, and 0.94 million people died due to colorectal cancer the same year globally.

Such increasing incidence of CRC and its increasing mortality rate has increased the demand for the detection of CRC and is expected to propel the global market growth in the coming years.

RESTRAINING FACTORS

Adverse Effects of Colonoscopies to Limit Colonoscopy Tests in the Future

Despite a serious and increased need for advanced and efficient screening procedures, certain limitations associated with the screening devices can limit their adoption.

For instance, colonoscopy is a highly accurate test and has the highest positivity rate. However, there are several side effects associated with the colonoscopy procedure, such as infection and bleeding, which can be caused to the patient after the colonoscopy procedure is done.

• According to the study published by NCBI in 2019, the perforation rate ranges from 0.005-0.085%, and post-colonoscopy bleeding occurs in 0.001-0.687% of cases. Moreover, the overall perforation rate trend during colonoscopy procedures in the past 15 years has not changed significantly.

Furthermore, there are several post-colonoscopy complications, such as severe pain or belly cramps, a hard belly, trouble passing gas or pooping, fever, dizziness, vomiting, frequent or severely bloody bowel movements, rectal bleeding that won't stop, or excess bleeding, which is anticipated to reduce the number of colonoscopy procedures during the forecast period.

Such limitations and adverse effects associated with colorectal cancer screening procedures are expected to hamper the market growth during the forecast timeframe.

Colorectal Cancer Screening Market Segmentation Analysis

By Type Analysis

High Positivity Rate Associated with Screening through Colonoscopies to Boost the Segment’s Growth

Based on type, the market is segregated into stool-based, colonoscopy, and others. The colonoscopy segment generated the highest revenue in 2023 and is expected to grow at a moderate CAGR during the forecast timeframe. The segment’s dominant share is attributed to the high accuracy of the procedure and the increasing incidence of colorectal cancer.

• For instance, according to World Cancer Research Fund International (WCRFI), in 2020, the estimated incidence of colorectal cancer was 1.9 million globally.

Furthermore, the stool-based segment is expected to grow at the highest rate during the forecast timeframe. The segment’s growth is due to the rising government programs for colorectal cancer screening and time-efficient results obtained from stool-based tests. The stool-based segment is further sub-segmented into fecal occult blood tests (gFOBT), fecal immunochemical tests (FIT/iFOBT), and stool-DNA tests. FIT screening tests are expected to grow at a significant CAGR during the forecast period due to their simple use and high positivity rate as compared to other stool-based tests.

By End-user Analysis

Strong Presence of Hospitals & Clinics to Boost Segment’s Growth

Based on end-user, the market is categorized into hospitals & clinics, clinical laboratories, diagnostic imaging centers, and others.

The hospitals & clinics segment accounted for a significant share of the market in 2023. Factors such as the presence of a substantial number of hospitals and the increasing number of CRC screening procedures conducted in hospitals are responsible for the segment’s growth.

The diagnostics imaging centers segment is estimated to grow at a significant CAGR during the forecast period. The increasing trend of colorectal cancer screening through colonoscopies and the increasing number of diagnostics centers conducting colonoscopy procedures across the world are some of the key factors contributing to the segmental growth.

REGIONAL INSIGHTS

The North America market generated USD 11.05 billion in 2023. The highly aware and economically stable population is a key factor for the large share of the market in North America. Moreover, the adoption of technologically advanced and high-cost tests, such as Cologuard, colonoscopies, and other stool-based tests in the region, is also expected to propel the market growth during the forecast period.

The market in Europe is expected to grow at a significant CAGR during the forecast period. Increasing demand for screening procedures such as stool-based testing in European countries, the presence of government programs, and rising awareness about the disease in key European countries are some of the major factors expected to boost market growth in Europe.

• For instance, United European Gastroenterology (UEG), with the European Code against Cancer, regulates CRC screening across Europe with organized, population-based screening programs and proactively promotes screening.

The market across Asia Pacific is expected to expand at a substantial CAGR in the projected years. The enhancement and improvement of healthcare facilities in Asian countries, increasing CRC incidence in the countries across the region, and the increasing consciousness of individuals in terms of better treatment outcomes are driving the regional market growth.

• For instance, as per a research article published by the National Center for Biotechnology Information (NCBI), in 2023, the incidence rate of colorectal cancer in Japan per 100,000 individuals was around 26.7 men and 22.7 women aged between 40 and 44.

The markets in Middle East & Africa and Latin America are also expected to expand at a significant CAGR during the forecast period. The increasing burden of the condition, rising government initiatives to create awareness about the disease along with easy availability of screening tests such as FIT and FOBT are responsible for the growth of the market for colorectal cancer screening across these regions.

List of Key Companies in Colorectal Cancer Screening Market

Companies with Strong Focus on Expansion of Screening Portfolio to Hold Key Market Share

Olympus Corporation, Exact Sciences Corporation, and Quest Diagnostics are the prominent players in the market and captured a considerable global colorectal cancer screening market share in 2023.

Olympus Corporation and Exact Sciences Corporation accounted for significant shares of the market in 2023. This was due to the company’s product portfolio for colonoscopy, which consists of efficient and technologically advanced colonoscopies.

Other significant players, including FUJIFILM Holdings Corporation, Laboratory Corporation of America Holdings, and Clinical Genomics Technologies Pty Ltd are emphasizing research and development activities for the launch of new and technologically advanced products in order to strengthen their market position.

• In October 2021, FUJIFILM Holdings Corporation announced the launch of its El-740D/S dual-channel endoscope. Fujifilm's EI-740D/S is the first dual-channel endoscope cleared by the U.S. Food and Drug Administration (FDA) for use in both lower and upper gastrointestinal applications.

LIST OF KEY COMPANIES PROFILED:

• NOVIGENIX SA (Switzerland)


• EIKEN CHEMICAL CO., LTD. (Japan)


• Clinical Genomics Technologies Pty Ltd. (U.S.)


• Exact Sciences Corporation  (U.S.)


• Epigenomics AG (Germany)


• bioMérieux, Inc. (France)


• Olympus Corporation (Japan)


• KARL STORZ SE & Co. KG (Germany)


• FUJIFILM Holdings America Corporation (Japan)

KEY INDUSTRY DEVELOPMENTS:

• February 2024 – Reese Pharmaceutical launched ColoTest, a home-based FIT colorectal cancer screening test.


• November 2023 – Guardant Health and Samsung Medical Center launched Shield, a blood-based CRC test, in South Korea.


• May 2022 – New Horizon Health and Prenetics announced their strategic partnership to launch ColoClear by Circle in China.


• March 2021 – Olympus Corporation announced the approval of Narrow Band Imaging (NBI) to assess the neoplastic potential of colorectal polyps by FDA 510(k). By applying the NBI International Colorectal Endoscopic (NICE) classification during a screening colonoscopy, physicians can make high-confidence predictions of histology for polyps 5mm or smaller, known as diminutive polyps.


• August 2020 – Olympus Corporation announced the acquisition of Arc Medical Design Limited (Arc Medical Design), a subsidiary of Norgine B.V. The acquisition helped the company in the development of advanced colonoscopy, thereby expanding its product portfolio for gastrointestinal therapeutics devices.

REPORT COVERAGE

The market research report provides a detailed competitive landscape. It includes the incidence of CRC and key industry developments such as partnerships, mergers, and acquisitions. Additionally, it focuses on key points such as new product launches in the market. Furthermore, the report covers regional analysis of different segments, company profiles of key market players, market trends, and the impact of COVID-19 on the market. The report consists of quantitative and qualitative insights that contribute to the market's growth.

Report Scope & Segmentation

ATTRIBUTE	DETAILS
Study Period	2019-2032
Base Year	2023
Estimated Year	2024
Forecast Period	2024-2032
Historical Period	2019-2022
Growth Rate	CAGR of 4.1% from 2024-2032
Unit	Value (USD billion)
Segmentation	By Type Stool-based Fecal Immunochemical Test (FIT) Fecal Occult Blood Test (FOBT) Stool-DNA Test Colonoscopy Others
By End-user Hospitals & Clinics Clinical Laboratories Diagnostic Imaging Centers Others
By Geography North America (By Type, End-user, and Country) U.S. Canada Europe (By Type, End-user, and Country/Sub-region) U.K. Germany France Italy Spain Scandinavia Rest of Europe Asia Pacific (By Type, End-user, and Country/Sub-region) Japan China India Australia Southeast Asia Rest of Asia Pacific Latin America (By Type, End-user, and Country/Sub-region) Brazil Mexico Rest of Latin America Middle East & Africa (By Type, End-user, and Country/Sub-region) GCC South Africa Rest of Middle East & Africa